{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:37:39Z","timestamp":1790753859415,"version":"4.1.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,4,1]],"date-time":"2024-04-01T00:00:00Z","timestamp":1711929600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,16]],"date-time":"2025-03-16T00:00:00Z","timestamp":1742083200000},"content-version":"am","delay-in-days":349,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP180674"],"award-info":[{"award-number":["RP180674"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["NCI-CA125123"],"award-info":[{"award-number":["NCI-CA125123"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","award":["RP220646"],"award-info":[{"award-number":["RP220646"]}],"id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020187","name":"Macy Easom Cancer Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1F32CA278313-01"],"award-info":[{"award-number":["1F32CA278313-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009429","name":"Israel National Road Safety Authority","doi-asserted-by":"publisher","award":["1F32CA278313-01"],"award-info":[{"award-number":["1F32CA278313-01"]}],"id":[{"id":"10.13039\/100009429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"DOD","doi-asserted-by":"publisher","award":["W81XWH-21-1-0396 \/ CD201061"],"award-info":[{"award-number":["W81XWH-21-1-0396 \/ CD201061"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2024,4]]},"DOI":"10.1016\/j.jhep.2024.01.003","type":"journal-article","created":{"date-parts":[[2024,1,21]],"date-time":"2024-01-21T00:30:27Z","timestamp":1705797027000},"page":"610-621","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma"],"prefix":"10.1016","volume":"80","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8716-3125","authenticated-orcid":false,"given":"Andres F.","family":"Espinoza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roma H.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalyani R.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5857-9495","authenticated-orcid":false,"given":"Andrew A.","family":"Badachhape","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Whitlock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit K.","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saiabhiroop R.","family":"Govindu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Duong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Kona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4449-8137","authenticated-orcid":false,"given":"Pavan","family":"Kureti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1025-0347","authenticated-orcid":false,"given":"Bryan","family":"Armbruster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina","family":"Kats","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramakrishnan R.","family":"Srinivasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6839-629X","authenticated-orcid":false,"given":"Lacey E.","family":"Dobrolecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3938-5924","authenticated-orcid":false,"given":"Xinjian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad J.","family":"Najaf Panah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Zorman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8094-0972","authenticated-orcid":false,"given":"Stephen F.","family":"Sarabia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Urbicain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karl-Dimiter","family":"Bissig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andras","family":"Heczey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-4977","authenticated-orcid":false,"given":"Pavel","family":"Sumazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores H.","family":"L\u00f3pez-Terrada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0515-5795","authenticated-orcid":false,"given":"Sarah E.","family":"Woodfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanjeev A.","family":"Vasudevan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2024.01.003_bib1","series-title":"StatPearls [Internet]","article-title":"Hepatoblastoma","author":"Musick","year":"2022"},{"issue":"9","key":"10.1016\/j.jhep.2024.01.003_bib2","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1470-2045(13)70272-9","article-title":"International Childhood Liver Tumours Strategy Group (SIOPEL). Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility study","volume":"14","author":"Zsiros","year":"2013","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.jhep.2024.01.003_bib3","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2022.04.035","article-title":"Hepatoblastomas with carcinoma features represent a biological spectrum of aggressive neoplasms in children and young adults","volume":"77","author":"Sumazin","year":"2022","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jhep.2024.01.003_bib4","doi-asserted-by":"crossref","first-page":"2360","DOI":"10.1002\/cncr.30591","article-title":"Upfront window vincristine\/irinotecan treatment of high-risk hepatoblastoma: a report from the Children's Oncology Group AHEP0731 study committee","volume":"123","author":"Katzenstein","year":"2017","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.jhep.2024.01.003_bib5","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2016.04.009","article-title":"Novel patient-derived xenograft and cell line models for therapeutic testing of pediatric liver cancer","volume":"65","author":"Bissig-Choisat","year":"2016","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2024.01.003_bib6","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1176790","article-title":"Targeted treatment of solid tumors in pediatric precision oncology","volume":"13","author":"Bertacca","year":"2023","journal-title":"Front Oncol"},{"issue":"13","key":"10.1016\/j.jhep.2024.01.003_bib7","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1158\/1078-0432.CCR-20-4224","article-title":"Activity of crizotinib in patients with ALK-aberrant relapsed\/refractory neuroblastoma: a children's oncology group study (ADVL0912)","volume":"27","author":"Foster","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jhep.2024.01.003_bib8","doi-asserted-by":"crossref","first-page":"100419","DOI":"10.1016\/j.jbo.2022.100419","article-title":"Targeting the IGF\/PI3K\/mTOR pathway and AXL\/YAP1\/TAZ pathways in primary bone cancer","volume":"33","author":"Truong","year":"2022","journal-title":"J Bone Oncol"},{"issue":"3","key":"10.1016\/j.jhep.2024.01.003_bib9","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11060-010-0402-7","article-title":"Phase II study of sunitinib malate in patients with recurrent high-grade glioma","volume":"103","author":"Neyns","year":"2011","journal-title":"J Neurooncol"},{"key":"10.1016\/j.jhep.2024.01.003_bib10","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/bs.acr.2018.02.006","article-title":"Advances and challenges of HDAC inhibitors in cancer therapeutics","volume":"138","author":"McClure","year":"2018","journal-title":"Adv Cancer Res"},{"issue":"3","key":"10.1016\/j.jhep.2024.01.003_bib11","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s00280-018-3634-4","article-title":"A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors","volume":"82","author":"Wood","year":"2018","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"10.1016\/j.jhep.2024.01.003_bib12","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1080\/15384047.2016.1235664","article-title":"Connectivity map identifies HDAC inhibition as a treatment option of high-risk hepatoblastoma","volume":"17","author":"Beck","year":"2016","journal-title":"Cancer Biol Ther"},{"issue":"5","key":"10.1016\/j.jhep.2024.01.003_bib13","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1016\/j.jcmgh.2021.06.026","article-title":"HDAC1-Dependent repression of markers of hepatocytes and P21 is involved in development of pediatric liver cancer","volume":"12","author":"Rivas","year":"2021","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.jhep.2024.01.003_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3892\/ijo.2022.5363","article-title":"Chimeric HDAC and the cytoskeleton inhibitor broxbam as a novel therapeutic strategy for liver cancer","volume":"60","author":"B\u00e4r","year":"2022","journal-title":"Int J Oncol"},{"issue":"60","key":"10.1016\/j.jhep.2024.01.003_bib15","doi-asserted-by":"crossref","first-page":"6403","DOI":"10.18632\/oncotarget.27237","article-title":"Volasertib preclinical activity in high-risk hepatoblastoma","volume":"10","author":"Kats","year":"2019","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.jhep.2024.01.003_bib16","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/pbc.23016","article-title":"Testing of the topoisomerase 1 inhibitor Genz-644282 by the pediatric preclinical testing program","volume":"58","author":"Houghton","year":"2012","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.jhep.2024.01.003_bib17","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1002\/hep.28888","article-title":"Genomic analysis of hepatoblastoma identifies distinct molecular and prognostic subgroups","volume":"65","author":"Sumazin","year":"2017","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.jhep.2024.01.003_bib18","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/sj.onc.1210204","article-title":"Discovery and development of SAHA as an anticancer agent","volume":"26","author":"Marks","year":"2007","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.jhep.2024.01.003_bib19","doi-asserted-by":"crossref","first-page":"pkz007","DOI":"10.1093\/jncics\/pkz007","article-title":"Trends in international incidence of pediatric cancers in children under 5 Years of age: 1988-2012","volume":"3","author":"Hubbard","year":"2019","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"10.1016\/j.jhep.2024.01.003_bib20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","article-title":"HDAC family: what are the cancer relevant targets?","volume":"277","author":"Witt","year":"2009","journal-title":"Cancer Lett"},{"issue":"23","key":"10.1016\/j.jhep.2024.01.003_bib21","first-page":"405","article-title":"Identification and experimental validation of druggable epigenetic targets in hepatoblastoma","author":"Claver\u00eda-Cabello","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jhep.2024.01.003_bib22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00428-011-1103-0","article-title":"Clinical significance of histone deacetylases 1, 2, 3, and 7: HDAC2 is an independent predictor of survival in HCC","volume":"459","author":"Quint","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1016\/j.jhep.2024.01.003_bib23","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.mri.2018.08.017","article-title":"Association among T2 signal intensity, necrosis, ADC and Ki-67 in estrogen receptor-positive and HER2-negative invasive ductal carcinoma","volume":"54","author":"Kim","year":"2018","journal-title":"Magn Reson Imaging"},{"issue":"4","key":"10.1016\/j.jhep.2024.01.003_bib24","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.28892","article-title":"A phase I study of entinostat in children and adolescents with recurrent or refractory solid tumors, including CNS tumors: trial ADVL1513, Pediatric Early Phase-Clinical Trial Network (PEP-CTN)","volume":"68","author":"Bukowinski","year":"2021","journal-title":"Pediatr Blood Cancer"},{"issue":"22","key":"10.1016\/j.jhep.2024.01.003_bib25","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2009.25.9119","article-title":"Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report","volume":"28","author":"Fouladi","year":"2010","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.jhep.2024.01.003_bib26","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1200\/JCO.2022.40.16_suppl.11553","article-title":"A phase I dose-escalation\/expansion clinical trial of mocetinostat in combination with vinorelbine in adolescents and young adults with refractory and\/or recurrent rhabdomyosarcoma: interim results","volume":"40","author":"Federman","year":"2022","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.jhep.2024.01.003_bib27","doi-asserted-by":"crossref","first-page":"5612","DOI":"10.1074\/jbc.M507213200","article-title":"Suberoylanilide hydroxamic acid potentiates apoptosis, inhibits invasion, and abolishes osteoclastogenesis by suppressing nuclear factor-kappaB activation","volume":"281","author":"Takada","year":"2006","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.jhep.2024.01.003_bib28","first-page":"1181","article-title":"Chemosensitization of oral squamous cell carcinoma cells to cisplatin by histone deacetylase inhibitor, suberoylanilide hydroxamic acid","volume":"30","author":"Rikiishi","year":"2007","journal-title":"Int J Oncol"},{"issue":"1","key":"10.1016\/j.jhep.2024.01.003_bib29","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"18","key":"10.1016\/j.jhep.2024.01.003_bib30","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1016\/j.ejca.2012.06.023","article-title":"Efficacy of irinotecan single drug treatment in children with refractory or recurrent hepatoblastoma--a phase II trial of the childhood liver tumour strategy group (SIOPEL)","volume":"48","author":"Zs\u00edros","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.jhep.2024.01.003_bib31","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.30365","article-title":"Vincristine\/irinotecan\/temsirolimus upfront window treatment of high-risk hepatoblastoma: a report from the Children's Oncology Group AHEP0731 Study Committee","author":"Thompson","year":"2023","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"10.1016\/j.jhep.2024.01.003_bib32","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.jhep.2024.01.003_bib33","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/bs.acr.2017.11.001","article-title":"Bcl-2 antiapoptotic family proteins and chemoresistance in cancer","volume":"137","author":"Maji","year":"2018","journal-title":"Adv Cancer Res"},{"issue":"11","key":"10.1016\/j.jhep.2024.01.003_bib34","first-page":"2554","article-title":"Correlation between chemosensitivity to anticancer drugs and Bcl-2 expression in gastric cancer","volume":"6","author":"Geng","year":"2013","journal-title":"Int J Clin Exp Pathol"},{"issue":"12","key":"10.1016\/j.jhep.2024.01.003_bib35","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1002\/1878-0261.13060","article-title":"Mechanistic insights into p53-regulated cytotoxicity of combined entinostat and irinotecan against colorectal cancer cells","volume":"15","author":"Marx","year":"2021","journal-title":"Mol Oncol"}],"updated-by":[{"DOI":"10.1016\/j.jhep.2026.05.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000}},{"DOI":"10.1016\/j.jhep.2026.05.005","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000}}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824000400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827824000400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:56:38Z","timestamp":1777510598000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827824000400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,4]]}},"alternative-id":["S0168827824000400"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2024.01.003","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel treatment strategy utilizing panobinostat for high-risk and treatment-refractory hepatoblastoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2024.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}